GlobeNewswire Inc | May 26, 2021 08:00AM EDT

May 26, 2021

LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the Jefferies Virtual Healthcare Conference taking place June 1 4, 2021.

Bruce Steel, Equilliums chief executive officer, and Dolca Thomas, M.D., Equilliums executive vice president of research and development and chief medical officer, will review each of the ongoing clinical programs in acute graft-versus-host disease, lupus/lupus nephritis and uncontrolled asthma. Mr. Steel, Dr. Thomas and other members of Equilliums leadership team will be available for one-on-one meetings during the conference.

Date: Wednesday, June 2, 2021Time: 11:00 AM Eastern Time | 8:00 AM Pacific TimeLocation: Virtual Webcast

A live webcast of the presentation will be available under the Investors section of the Companys website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.

About EquilliumEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visitwww.equilliumbio.com.

Investor ContactMichael Moore Vice President, Investor Relations & Corporate Communications+1-619-302-4431ir@equilliumbio.com

Media ContactsAljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com